Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111)
Hussain M, Faulkner J, Vaishampayan U, Lara P, Petrylak D, Colevas D, Sakr W, Crawford E. Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111). Journal Of Clinical Oncology 2004, 22: 4510-4510. DOI: 10.1200/jco.2004.22.14_suppl.4510.Peer-Reviewed Original ResearchEpothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111)
Hussain M, Faulkner J, Vaishampayan U, Lara P, Petrylak D, Colevas D, Sakr W, Crawford E. Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111). Journal Of Clinical Oncology 2004, 22: 4510-4510. DOI: 10.1200/jco.2004.22.90140.4510.Peer-Reviewed Original Research